| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd5aa8caf72702076c71578e5434e69f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2020-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f95622ccd81207313deed9281820a9b4 |
| publicationDate |
2020-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020242837-A1 |
| titleOfInvention |
A precision medicine method for cancer immunotherapy |
| abstract |
Cancer immunotherapy has achieved immense clinical success with long survival even in the most difficult to treat cancer. Yet this effect is only observed in a minority and there are no biomarkers of this response. The methods described herein improve cancer immunotherapy outcomes using two independent measures of systemic chronic inflammation (the inflammatory age -iAge- and cytokine response score -CRS) to stratify cancer patients into responders versus non-responders to cancer immunotherapy. The iAge personalized immune proteome signature creates an individualized initial therapy to reduce iAge and to convert non-responders patients into responders prior to treatment. Nonresponders can be converted to responders by treating the patients to reduce their iAge and improve their CRS. |
| priorityDate |
2019-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |